cbdMD Bets on a Medicare Pathway to Rewrite the CBD Playbook
A Small-Cap Surprise
cbdMD's second fiscal quarter of 2026 was a far cry from routine. The company posted net sales of $5.6 million, up 19% year-over-year and 12% sequentially, with core business (ex-Bluebird) adding roughly $500K versus the prior year. That core growth is the clearest sign yet that the multi-year reset is taking hold. As CEO Ronan Kennedy put it, “we delivered another consecutive quarter of sequential revenue growth, with net sales of $5.6 million, up 19% year-over-year and 12% sequentially.” — T. Kennedy, Chief Executive Officer · 2026-05-14 The growth comes even as the mix shifts to wholesale (33% of revenue vs. 23% a year ago) and gross margin dipped to 58% from 62%, a cost of doing business in a category where state-level regulation is a constant tax on compliance. CFO Brad Whitford noted the margin pressure is "mostly attributable to a shift in revenue mix to more wholesale, including Oasis, along with incremental costs related to changes in state-level requirements causing additional repacking and new testing requirements." The NYSE American listing remains a hard-won asset, and management is now using it to pursue disciplined M&A—first with Bluebird.
Bluebird: The First Real Test of M&A Discipline
The Bluebird Botanicals acquisition closed in mid-January, and the second quarter absorbed transition costs without a full quarter of contribution. Yet management expects it to flip to a positive contributor in Q3, citing strong March and April trends and a "very strong April with the brand." The strategic rationale extends beyond revenue: Bluebird brings a loyal customer base and full-spectrum formulations that complement cbdMD's THC-free broad-spectrum portfolio. The company is already realizing supply-chain and product synergies, and it plans to evaluate further accretive deals. "We believe we're pretty much fully integrated, had a good March, had a very strong April," Kennedy said, adding that the integration is "off to a good quarter, a profitable quarter." The bigger story, however, is the regulatory shift that could redefine the entire industry.
A New Frontier: The CMS BEI Program
The single most consequential development in this report is the activation of the CMS substance access beneficiary engagement incentive (BEI) on April 1, 2026—the first federal pathway for hemp-derived CBD products in Medicare. This is not a market-wide theme; it is company-specific and unprecedented. Management has already stood up a dedicated clinical and healthcare channel, begun talks with ACOs, and is deepening its clinical evidence base. Kennedy was explicit that this is a long-term bet: "We accept the near-term earnings pressure because we believe the long-term opportunity is meaningful and because the window to establish provider relationships and clinical credibility is open now." The CMS BEI program is a genuine catalyst, but the company is also building contingency plans around the November 2026 effective date of the Hemp Act, actively engaging with policymakers on HEMP Act revisions and broader federal reform. The shift in tone from prior quarters is stark. On the December 2025 call, management was still digesting the executive order and the uncertainty of the November bill; now they speak with conviction about a "sizeable, once-in-a-generation opportunity."
This regulatory push is not without risk. State-level volatility continues to create chaos—most notably in Alabama, where a new law effectively halted sales of hemp-derived Delta-9 products. Nationally, the reversal of the cannabis rescheduling to Schedule III adds another layer of uncertainty. Yet cbdMD's positioning as a compliance-first, clinically-backed supplier is exactly the profile that should benefit as the federal framework matures. The company is also using its balance sheet deliberately: it closed an equity facility (ELOC) and authorized a reverse stock split as a defensive measure, but management reiterates that no split is planned. "Right now, there is no plan to execute a reverse," Kennedy noted, "it is more to make sure we have it available."
Financial Trajectory
The numbers still show losses, but the trend is improving. Total revenue for the quarter reached $6M (rounded) with a 19% year-over-year gain, while the net loss attributable to common shareholders narrowed to $0.08 per share from $1.90 a year earlier, driven largely by the elimination of the Series A preferred dividend. Operating loss was $801K (or $405K ex-onetime stock vesting), and adjusted EBITDA loss was $220K. Cash used in operations was $723K, reflecting an AR build tied to wholesale growth and a deliberate inventory build—both of which management expects to normalize. With $2.6M in cash and the ELOC in place, the company believes it has enough runway to execute its investing plan without near-term dilution. Analyst Adam Waldo pressed on breakeven, and Kennedy offered a clear signal: "I think it should be well below $7 million" quarterly revenue, implying a path to profitability sooner than the market might expect.
The foundation we've built over the past several years is showing through, and we believe cbdMD is entering the second half of 2026 on firmer footing than at any point in recent memory.
Why It Matters
cbdMD is a micro-cap with a market cap under $10M, but it is positioning itself at the intersection of a potential federal tailwind (Medicare reimbursement for CBD) and an operational turnaround. The company's pathway to relevance is through regulatory first-mover advantage, clinical credibility, and disciplined execution. If the BEI program gains traction over the next 12–18 months, cbdMD could become a prime beneficiary in a historically fragmented and repressed category. The stock is down 25% over the last 90 days, but that likely reflects broader market volatility and the cost of the strategic pivot, not a fundamental breakdown. This is a name to watch—not for today's earnings, but for the optionality that a federal 'first' creates.